Alnylam ALNY
First Signal's file · in 1 issue · All companies
RNA drugs for rare heart and nerve diseases
Every time it made the issue
We cover a company only when it moves enough to matter. Each row is one of those days, what we made of it, and how the stock did over the next 5 and 20 trading days, next to the S&P 500.
| Date | Where | Move | Our read | 5 days later | 20 days later |
|---|---|---|---|---|---|
| Thu, Oct 29, 2026 | Earnings | −25.1% | Product sales rose 52% to $1.29 billion, but it enlarged a key heart study of its next drug to 2,250 patients, with a launch still expected by 2030. | to come | to come |
Its biggest days of the past ten years
| Best days | Move |
|---|---|
| Wed, Sep 20, 2017 | +51.7% |
| Wed, Aug 3, 2022 | +49.3% |
| Mon, Jun 24, 2024 | +34.5% |
| Worst days | Move |
|---|---|
| Thu, Oct 6, 2016 | −48.5% |
| Thu, Jul 30, 2026 | −28.3% |
| Thu, Oct 29, 2026 | −25.1% |
How it took its last 8 reports
The stock's move in the first session after each quarterly report. Next report: not yet announced.
| Results filed | Next session |
|---|---|
| Thu, Oct 29, 2026 | −25.1% |
| Thu, Jul 30, 2026 | −28.3% |
| Thu, Apr 30, 2026 | +2.8% |
| Thu, Feb 12, 2026 | −4.3% |
| Thu, Oct 30, 2025 | −6.7% |
| Thu, Jul 31, 2025 | +15.4% |
| Mon, Jan 13, 2025 | +8.5% |
| Thu, Feb 15, 2024 | −10.2% |
Moves are daily closing prices. Past moves don't predict future ones.